Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
Inserm · Institut Gustave Roussy · +26 more institutions
Abstract
Advancements in the field of precision medicine have prompted the European Society for Medical Oncology (ESMO) Precision Medicine Working Group to update the recommendations for the use of tumour next-generation sequencing (NGS) for patients with advanced cancers in routine practice.
The group discussed the clinical impact of tumour NGS in guiding treatment decision using the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) considering cost-effectiveness and accessibility.
Citation impact
- FWCI
- 84.60
- Percentile
- 100%
- References
- 200
Authors
23- MMM.F. Mosele
Inserm, Institut Gustave Roussy
- CBC. Benedikt Westphalen
LMU Klinikum, Comprehensive Cancer Center Vienna, Ludwig-Maximilians-Universität München
- ASA Stenzinger
Heidelberg University, University Hospital Heidelberg
- FBFabrice Barlési
Inserm, Université Paris-Saclay, Institut Gustave Roussy
- ABAriane Bayle
Inserm, Université Paris-Saclay, Institut Gustave Roussy, La Ligue Contre le Cancer
Topics & keywords
- Medicine
- Precision medicine
- Oncology
- Cancer
- Internal medicine
- Prostate cancer
- Colorectal cancer
- Lung cancer